PCRX earnings / call / takeaways

PCRX Q3 FY26 earnings call: key takeaways

What PCRX said on its earnings call of November 5, 2026: results against expectations, what changed since last quarter, guidance and the questions analysts pressed on.

By Lician·November 5, 2026·AI-generated from the call transcript and Lician data

The company raised its 2026 financial guidance across all key metrics. The main message of the call was continued growth and strong performance in North America and Greater China. (11:54)

Results vs expectations

Metric	Consensus	Reported	Result
EPS	$0.47	–	–
Revenue	$182.9M	–	–

What changed since last quarter

The company raised its 2026 financial guidance, now expecting operational growth of approximately 2% for total revenues, 6% for adjusted EBITDA, and 8% for adjusted EPS. (25:50)
The company expects the acquisition of Pacera to contribute meaningfully to long-term growth and to add more than $50 million in annual cost synergies by 2028. (27:30)
The CEO highlighted the importance of the acquisition of Pacera, noting it would strengthen the U.S. innovative medicines business and add durable revenue and margins. (14:32)

Guidance

Metric	This call	Previous call
Revenue	Full-year revenue guidance raised to 2% growth (25:50)	not captured
EBITDA	Full-year adjusted EBITDA guidance raised to 6% growth (25:50)	not captured
EPS	Full-year adjusted EPS guidance raised to 8% growth (25:50)	not captured

What analysts pressed on

Whether the hospital procurement policy in China will continue to moderate growth. (30:41)
Questions about the potential loss of exclusivity for products like Amitiza and Sulfan Blue in 2027. (38:50)

In their words

We believe we've entered a new phase of sustained growth for VHRs. Scott Smith (11:54)
We expect our U.S. innovative medicines business to generate more than a billion dollars in total revenue in 2027. Scott Smith (14:32)

Read the full transcript with the AI summary, or listen on the company's official webcast.

Every past call in full and transcript search come with Lician Pro.

Written by AI from the automatic transcript of the company's public webcast and Lician's earnings data. Each sentence cites the passage it comes from, and a sentence with a figure that is not in its sources was removed. Not investment advice.